Agilent has posted a strong Q2, so much so that the company has raised full year guidance. Revenue for the quarter was $1.02 billion, an increase of 6% compared with the same period last year. Net income rose 5% to $91 million.
“Agilent delivered another strong quarter,” said Mike McMullen, Agilent president and CEO. “Revenue and earnings per share exceeded our guidance range. We saw broad growth across most of our portfolio and end markets.”
“We continue to execute on our strategy to drive sustainable growth, expand operating margins and provide long-term value to our shareholders,” he added.
The company reports revenues based on three key segments of their business. The Life Sciences and Applied Markets Group which represents 49% of the total business, saw sales grow by 4.7% to $495 million. The diagnostics and Genomics Group which accounts for 17.5% of total sales also saw growth of 5.3% to $178 million and the Agilent CrossLab Group saw growth of 7.8% to $346 million for the quarter.